Skip to content
Quant500 - Quantitative Analysis
Search ticker or company...
ES | EN

Company Profile: Johnson & Johnson (JNJ)

JNJ insider trades (13 months) →

$266.17 −1.62% vs. previous close · Market cap $640.75B

Today's multi-factor rank: 133 of 461 · see the ranking

Quant500 Scores
Momentum
7.3/10
Value
4.0/10
Growth
4.1/10
Quality
5.5/10
Multifactor
5.2/10

Market and Valuation

Price & Market

Prev Close Price:$270.56
Open:$268.51
Day's Low:$265.29
Day's High:$271.07
Bid / Ask:-
Market Cap:640.75B
Enterprise Value:678.74B

52-Week Range

52-Week Low:$185.12
52-Week High:$282.02
Current position in 52-week range
52w Low-52w High
50-Day Avg:$265.61
200-Day Avg:$247.24

Volume

Volume Today:6,471,685
Avg Volume (3m):6,890,648
Avg Volume (10d):7,083,210
52-Week Change:+44.79%
vs S&P 500, 52 weeks:-
Beta:0.20

Valuation Multiples

P/E (trailing):40.39

Diluted EPS for the last 12 months: the four quarters ended Sep 27, 2026, from the accounts filed with the SEC on Oct 21, 2026. The P/E is the price divided by that EPS.

P/E (forward):22.91
PEG Ratio:3.04
Price / Book:7.86
Price / Sales (TTM):6.45
EV / Revenue:6.83
EV / EBITDA:19.67

Dividends

Current yield:1.98%
Annual Dividend Rate:$5.36
Dividend Trailing:$5.28
Yield Trailing:1.95%
5-Year Avg Yield:2.67%
Payout Ratio:80.12%
Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-
Fiscal Year (Next):-

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):99.33B
Gross Profit:67.32B
EBITDA:34.50B
Net Income (TTM):16.09B
Rev Growth (YoY):+5.90%
Earnings Growth (YoY):-95.90%
Quarterly earnings growth (YoY):-95.90%

Margins

Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-

Per Share

EPS Trailing (TTM):$6.59

Diluted EPS for the last 12 months: the four quarters ended Sep 27, 2026, from the accounts filed with the SEC on Oct 21, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$11.62
Revenue Per Share:$41.25
Cash Per Share:-
Book Value:$33.87
Last Dividend:-
Ex-Dividend Date:-
Last Split:-

Balance Sheet & Liquidity

Total cash:17.23B
Total Debt:44.65B
Net Debt (Debt - Cash):27.42B
Debt / Equity:54.77%
Current Ratio:1.02
Quick Ratio:0.65

Cash Flows

Operating Cash Flow:26.16B
Free Cash Flow (FCF):18.50B
FCF Yield (FCF / Market Cap):-
Enterprise Value:678.74B
EV / Revenue:6.83
EV / EBITDA:19.67

Profitability

ROE (Return on Equity):20.02%
ROA (Return on Assets):8.46%
P/E (trailing):40.39
P/E (forward):22.91
Price / Book:7.86
PEG Ratio:3.04
52-Week Change:+44.79%
S&P 500 change, 52 weeks:+11.37%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$6.59

Diluted EPS for the last 12 months: the four quarters ended Sep 27, 2026, from the accounts filed with the SEC on Oct 21, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$11.62
P/E (forward):22.91
PEG Ratio:3.04

Growth and Margins

Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-

Per Share

Revenue Per Share:$41.25
Cash Per Share:-
Book Value:$33.87

Cash Flows (TTM)

Free Cash Flow:18.50B
Operating Cash Flow:26.16B
EBITDA:34.50B
Total Revenue (TTM):99.33B
Net Income (TTM):16.09B
Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter Period Actual EPS Estimated EPS Difference Surprise % Currency

Ownership Structure

Ownership Distribution

% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:2,407,310,266
Float (free shares):2,403,386,350
Short interest (shares):16,766,729
Short % of float:-
Short Ratio (days to cover):2.23
Short interest, prior month:-
Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization Report Date % Shares No. Shares Value (USD) Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund Report Date % Shares No. Shares Value (USD) Change %

Recent Insider Trades

Executive / Insider Title Date Action Shares

Options Chain

CALLS

StrikeLastBidAskVol.O.I.IV

PUTS

StrikeLastBidAskVol.O.I.IV

Johnson & Johnson (JNJ) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type Date Official link
10-Q2026-10-21View filing ↗
8-K2026-10-13View filing ↗
N-PX2026-08-11View filing ↗
8-K2026-08-04View filing ↗
8-K2026-07-29View filing ↗
8-K2026-07-28View filing ↗
10-Q2026-07-23View filing ↗
8-K2026-07-15View filing ↗
11-K2026-06-25View filing ↗
SD2026-05-27View filing ↗

Company and Executive Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

General Information

Headquarters:United States
City:New Brunswick
Employees:138,200
Sector:Healthcare
Industry:Drug Manufacturers - General
Website:-

Key Executives

NameTitleAgeTotal pay
Mr. Joaquin DuatoCEO & Chairman626.50M
Mr. Joseph James Wolk CPAExecutive VP & CFO583.22M
Dr. John C. Reed M.D., Ph.D.Executive Vice President of Innovative Medicine and R&D673.17M
Mr. Timothy SchmidExecutive VP & Worldwide Chairman of MedTech552.54M
Mr. Robert J. Decker Jr.Controller & Chief Accounting Officer52-
Mr. James SwansonExecutive VP & Chief Information Officer59-
Mr. Ryan KoorsVice President of Investor Relations--
Mr. Dirk BrinckmanChief Compliance Officer--

You have seen the engine room

A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.

No card. No spam.

Johnson & Johnson (JNJ): Quantitative Analysis

Johnson & Johnson (JNJ) — Healthcare — Drug Manufacturers - General. JNJ is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, JNJ has returned +30.5% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.

JNJ ranks 133 of 461 on today's multifactor score, and 13 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 1.35, ranked 41 of 494); its weakest is value (Z -0.61, ranked 422 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

FactorZ-ScoreRank
Multifactor0.137133 of 461
Momentum1.35441 of 494 ↓5
Value-0.609422 of 489 ↑1
Quality0.317113 of 468 ↓1
Growth-0.512419 of 489

Market data

MetricValue
Price$266.17
Market Cap640.75B
P/E40.39
Revenue (last 12 months)99.33B
Price / book7.86
Book value per share$33.87
52-week range$185.12 – $282.02
Dividend yield1.98%
Beta0.20
Average volume6,890,648
Shares outstanding2.41B
Short interest (% of float)0.78% (as of Oct 15, 2026)

When does JNJ report earnings? 12 of its last 12, before the open →

What are JNJ insiders doing? 88 transactions filed with the SEC, of them 1 buy and 19 sells, the last one on Sep 2, 2026 →

JNJ latest SEC filings

Filing dates on EDGAR, the SEC's public registry. All JNJ filings on EDGAR.

Guides: How to read a Quant500 company page · What the S&P 500 is · P/E ratio explained · 10-K, 10-Q and 8-K · all guides

Frequently asked questions about Johnson & Johnson (JNJ)

When does Johnson & Johnson report earnings?

Johnson & Johnson has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 before the open (SEC filings through Oct 13, 2026). JNJ earnings dates and times, quarter by quarter →

What is Johnson & Johnson's P/E ratio?

Johnson & Johnson's P/E (price over earnings per share for the last twelve months) is 40.4 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 27, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Johnson & Johnson is above its sector median. Healthcare stocks, company by company →

Where does Johnson & Johnson rank on Quant500?

In the Nov 3, 2026 multi-factor ranking, Johnson & Johnson ranks 133 of 461, and 13 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking → How it is calculated →

Have Johnson & Johnson insiders bought or sold shares?

The latest open-market purchase of Johnson & Johnson shares filed with the SEC (Form 4) was on Nov 26, 2025, by a director, for $258k. The latest sale was on Sep 2, 2026, by an officer, for $9.2M. In total, from August 2025 through Nov 3, 2026: 1 purchase and 19 sales by directors, officers and large shareholders. All JNJ insider trades →

Does Johnson & Johnson pay a dividend?

Yes. Its dividend yield is 1.98% at the Nov 3, 2026 close (annual dividend of $5.36 per share). The next announced ex-dividend date is Nov 24, 2026.

What sector is Johnson & Johnson in, and which index?

Johnson & Johnson is classified in the Healthcare sector (industry: Drug Manufacturers - General), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →

What is behind these numbers

The concepts on this page, explained from scratch in the Academy. Free, no account.

The whole Academy, course by course →

Data as of Nov 3, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

The model portfolio, weekly in your inbox

Every Saturday, its week in one minute: how it went, the best and the worst, and which insiders bought with their own money. Plus, the day the model is rebuilt, which stocks come in and which go out. A simulation, not advice. At most one email a week, no ads, no account; one-click unsubscribe. Made by one person: Pol Gracia.

A model portfolio with simulated results, not a personalized recommendation. Your email is used for this only: privacy.

S&P 500 market gravity